Population pharmacokinetics of intravenous and oral panobinostat in patients with hematologic and solid tumors

A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function

(2014) Sunil Sharma et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function

(2014) Marije Slingerland et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A clinical investigation of inhibitory effect of panobinostat on CYP2D6 substrate in patients with advanced cancer

(2013) Ronald Feld et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors

(2013) Sunil Sharma et al.   INVESTIGATIONAL NEW DRUGS

A Pharmacokinetic Standard for Babies and Adults

(2013) Nick Holford et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies

(2013) D J DeAngelo et al.   LEUKEMIA

Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients

(2012) Sally Clive et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial

(2012) Madeleine Duvic et al.   EUROPEAN JOURNAL OF CANCER

A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors

(2012) Akira Fukutomi et al.   INVESTIGATIONAL NEW DRUGS

Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study

(2012) Anas Younes et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma

(2012) Jeffrey L. Wolf et al.   LEUKEMIA & LYMPHOMA

The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer

(2011) Geoffrey I. Shapiro et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor

(2011) Paul Hamberg et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges

(2009) Peter Atadja   CANCER LETTERS

Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors

(2009) H Miles Prince et al.   Future Oncology